These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
204 related articles for article (PubMed ID: 6810123)
1. [Carbohydrate metabolism in bezafibrate therapy. Controlled study of glibenclamide-treated diabetics with hyperlipidemia]. Janka HU; Standl A; Holler HD; Mehnert H MMW Munch Med Wochenschr; 1982 May; 124(21):535-7. PubMed ID: 6810123 [No Abstract] [Full Text] [Related]
2. [Effect of bezafibrate on the carbohydrate metabolism of 17 diabetics with hyperlipidemia]. Stratmann FW; Holler HD; Hofmann H Med Welt; 1981 Feb; 32(8):268-71. PubMed ID: 7207168 [No Abstract] [Full Text] [Related]
3. [Therapeutic effects of bezafibrate in hyperlipidemia]. Kunesová M; Honková M; Zeman M; Mares P; Skorepa J Cas Lek Cesk; 1983 May; 122(20):628-31. PubMed ID: 6342789 [No Abstract] [Full Text] [Related]
4. Improvement of hyperlipidaemia by bezafibrate treatment in RDT patients. Grützmacher P; Scheuermann E; Lang W Proc Eur Dial Transplant Assoc; 1981; 18():169-75. PubMed ID: 7036147 [TBL] [Abstract][Full Text] [Related]
5. [Improvement in diabetes control by treatment with bezafibrate]. Rüth E; Vollmar J Dtsch Med Wochenschr; 1982 Oct; 107(39):1470-3. PubMed ID: 6749468 [TBL] [Abstract][Full Text] [Related]
6. [What are the possibilities in the treatment of primary hyperlipidemia in diabetes mellitus?]. Stratmann FW Med Welt; 1982 Apr; 33(17):651. PubMed ID: 7098830 [No Abstract] [Full Text] [Related]
7. The antilipemic effectiveness of aluminium clofibrate on hyperlipidemic patients with or without diabetes mellitus. Lam HC; Li SH; Wang JT; Tang KT; Ho LT Zhonghua Yi Xue Za Zhi (Taipei); 1987 Nov; 40(5):463-70. PubMed ID: 3332236 [No Abstract] [Full Text] [Related]
8. [Treatment of hyperlipoproteinaemia in diabetic patients (author's transl)]. Bruneder H; Klein HJ Dtsch Med Wochenschr; 1981 Dec; 106(49):1653-6. PubMed ID: 7308007 [TBL] [Abstract][Full Text] [Related]
9. [Lipid-lowering effect of bezafibrate in patients with diabetes mellitus and hyperlipidaemia (author's transl)]. Wahl P; Hasslacher C; Lang PD; Vollmar J Dtsch Med Wochenschr; 1978 Aug; 103(31):1233-7. PubMed ID: 668570 [TBL] [Abstract][Full Text] [Related]
10. [Bezafibrate and delayed action etofibrate in hyperlipidemia]. Lang PD; Vollmar J Dtsch Med Wochenschr; 1983 Feb; 108(8):302-5. PubMed ID: 6825604 [No Abstract] [Full Text] [Related]
11. [Effect of bezafibrate on lipid and apoprotein levels in patients with idiopathic hypertriglyceridemia]. Naruszewicz M; Nowicka G; Szostak WB; Kłosiewicz-Latoszek L Kardiol Pol; 1982; 25(7-8):527-31. PubMed ID: 7169740 [No Abstract] [Full Text] [Related]
12. Clinical research into the hypolipemic and platelet antiaggregant activity of plafibride, Carried out in double-blind conditions and in comparison with clofibrate. Palmieri B; Gasparini Casari M; DiBlasio P; Zirilli E Arzneimittelforschung; 1981; 31(10a):1863-6. PubMed ID: 7032534 [TBL] [Abstract][Full Text] [Related]
13. [Efficacy of bezafibrate and fenofibrate on elevated blood lipids in HLP type IIa, IIb and IV]. Schwartzkopff W; Luley C; Scheffler W; Lehmann-Leo W; Schilling A; Wegscheider K Med Welt; 1982 Apr; 33(17):631-7. PubMed ID: 7098826 [No Abstract] [Full Text] [Related]
14. [Study of the antilipemic effect of etofibrate (Lipo-Merz)]. Słowińska R; Bochenek W; Unlot J Pol Tyg Lek; 1983 Apr; 38(17):529-32. PubMed ID: 6356087 [No Abstract] [Full Text] [Related]
15. [Lipid-lowering effect of etofibrate, bezafibrate and xanthinol nicotinate in patients with hyperlipoproteinemias]. Machalke K; Djaja S; Richter E Ther Ggw; 1982 May; 121(5):301-11. PubMed ID: 6953613 [No Abstract] [Full Text] [Related]
16. [A comparison of bezafibrate and clofibrate in type II B and type IV hyperlipoproteinemia]. Bolzano K; Krempler F; Schellenberg B; Schlierf G Acta Med Austriaca; 1979; 6(3):90-4. PubMed ID: 547652 [TBL] [Abstract][Full Text] [Related]
17. [Double-blind study of the therapeutic activity of a new hypolipemic drug: etofibrate]. Altomonte L; Mingrone G; Negrini A; De Cunto F; Greco AV Clin Ter; 1981 Jan; 96(1):31-8. PubMed ID: 7016409 [No Abstract] [Full Text] [Related]
18. [An alternative in the therapy of primary hyperlipemias: etofibrate in depot preparations]. Füsgen I; Summa JD Med Klin; 1980 Nov; 75(23):823-5. PubMed ID: 7442597 [TBL] [Abstract][Full Text] [Related]
19. [Use of etofibrate in the treatment of patients with hyperlipidemia and arteriosclerosis obliterans of the legs]. Dembińska-Kieć A; Kostka-Trabka E; Grodzińska L; Bieroń K; Kedzior A; Basista M; Zmuda A; Trabka E; Sławiński M; Czarnecka B Pol Tyg Lek; 1987 Dec 21-28; 42(51-52):1643-8. PubMed ID: 3330798 [No Abstract] [Full Text] [Related]
20. [Pharmacology and mechanism of action of etofibrate]. Schatton W Med Welt; 1982 Sep; 33(38):1310-4. PubMed ID: 6752630 [No Abstract] [Full Text] [Related] [Next] [New Search]